This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Technologies and Applications Digital Week
September 27 - 28, 2022
2-day free-to-attend webcast series

Orla Cunningham
CSO at UltraHuman


Following a postdoc in cancer cell biology, Orla returned to Ireland to establish Wyeth’s nascent antibody discovery & engineering group which was subsequently acquired by Pfizer. Throughout her career at Pfizer, Orla led multi-disciplinary project teams internally as well as academic collaborations with universities across Ireland & the UK. She has supported pre-clinical programs from conception through development, with a number of these molecules currently progressing through clinical trial.

Before joining Ultrahuman Eight as CSO, Orla was Senior Director of Pfizer’s biotherapeutic discovery & optimization group, sitting on the global leadership team. She has published widely in the field of therapeutic antibody engineering & is co-author of several patents.

Agenda Sessions

  • Sequential Paratope Refinement Transforms a Polyspecific PD1 Antibody into a Truly Unique Bifunctional PD1/VEGFR2 Antagonist